MOR 201

Drug Profile

MOR 201

Latest Information Update: 31 Jul 2003

Price : $50

At a glance

  • Originator MorphoSys; ProChon Biotech
  • Developer MorphoSys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fibroblast growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 31 Jul 2003 Discontinued - Preclinical for Haematological malignancies in Germany (unspecified route)
  • 27 Jun 2003 MOR 201 is available for licensing (
  • 02 May 2002 Preclinical trials in Haematological malignancies in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top